TREATING WITH RYSTIGGO

TREATING WITH RYSTIGGO

RYSTIGGO is administered by a healthcare
professional as a weekly subcutaneous
infusion for a 6-week treatment cycle1

Once-weekly,

subcutaneous infusion

administered by a healthcare professional1*

6-week cyclic treatment

with weekly dosing, followed by an individualized dosing schedule for subsequent cycles based on clinical evaluation1

Once-weekly, subcutaneous infusion

administered by a healthcare professional1*

6-week cyclic treatment

with weekly dosing, followed by an individualized dosing schedule for subsequent cycles based on clinical evaluation1

RYSTIGGO is a once-weekly subcutaneous infusion administered in approximately 15 minutes once preparation is complete1

~15 minutes.

Administration:

  • Time of administration may vary by patient. Duration of infusion may be longer based on flow rate and patient weight1
  • RYSTIGGO is intended to be infused in the lower right or lower left part of the abdomen below the navel1
  • Do not infuse where the skin is tender, bruised, red, or hard. Avoid infusing into tattoos, scars, or stretch marks1
  • Rotate infusion sites for subsequent administrations1

Observation:

  • Monitor patients during treatment with RYSTIGGO and for 15 minutes after completion for clinical signs and symptoms of hypersensitivity reactions. If a reaction occurs, institute appropriate measures if needed1
  • In clinical trials, hypersensitivity reactions occurred within 1 day to 2 weeks of administration. One patient discontinued RYSTIGGO due to a hypersensitivity reaction. Local reactions at the administration site occurred within 1 to 3 days after the most recent RYSTIGGO infusion1
6-week RYSTIGGO® treatment cycle.
6-week RYSTIGGO® treatment cycle.

In RYSTIGGO clinical studies1:

  • 8 weeks of observation followed the 6-week treatment period
    • The safety of initiating subsequent cycles sooner than 9 weeks (63 days) from the start of the previous treatment cycle has not been established
  • 4 treatment cycles were initiated per year, on average (range: 1-7 cycles)

RYSTIGGO dosage is based on body weight1

RYSTIGGO is supplied in 280 mg/2 mL (140 mg/mL) single-dose vials1

Body weight of patient
Dose
Dosage volume
Vials per dosage
Vials per cycle
<50 kg
420 mg
3 mL
2 vials
12 vials
50 to <100 kg
560 mg
4 mL
2 vials
12 vials
≥100 kg
840 mg
6 mL
3 vials
18 vials
Body weight of patient
<50 kg
50 to <100 kg
≥100 kg
Dose
420 mg
560 mg
840 mg
Dosage volume
3 mL
4 mL
6 mL
Vials per dosage
2 vials
2 vials
3 vials
Vials per cycle
12 vials
12 vials
18 vials
  • RYSTIGGO is administered as a subcutaneous infusion
    once weekly for 6 weeks1
    • If a scheduled infusion is missed, RYSTIGGO may
      be administered up to
      4 days after
      the scheduled
      time point1
    • Thereafter, resume the original dosing schedule
      until the treatment
      cycle is completed1

RYSTIGGO infusions can be administered in different settings

RYSTIGGO is for subcutaneous administration only using an infusion pump. Refer to the infusion pump manufacturer’s instructions for full preparation and administration information. It is recommended to use pumps where administered volume can be preset, as each vial contains excess volume for priming of the infusion line.1

Physician office infusion suite

Physician office infusion suite

These physician offices have capabilities to both prescribe and infuse RYSTIGGO.

Register your practice with the RYSTIGGO Infusion
Center Finder

REGISTER YOUR PRACTICE

Independent infusion center

Independent infusion center

These centers are independent from physician offices and hospitals. Infusion nurses staff these centers; physicians may or may not be on-site.

Find an infusion center for your gMG patients

INFUSION CENTER FINDER

Home infusion

Home infusion

Some patients may be eligible for RYSTIGGO to be administered at home by a trained nurse. Eligibility is based on a patient’s insurance plan. Not all patients are eligible.

Hospital outpatient department

Hospital outpatient department

These facilities exist within hospitals for patients who do not need to be admitted to receive infusions.

Administration considerations with RYSTIGGO1

Infections

  • Delay RYSTIGGO administration in patients with an active infection until the infection is resolved

Immunization

  • Because RYSTIGGO causes a reduction in IgG levels, vaccination with live-attenuated or live vaccines is not recommended during treatment with RYSTIGGO

Hypersensitivity Reactions

  • If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention

Effect of RYSTIGGO on other drugs

  • Concomitant use of RYSTIGGO with medications that bind to the human neonatal Fc receptor (FcRn) (eg, immunoglobulin products, monoclonal antibodies, or antibody derivatives containing the human Fc domain of the IgG subclass) may lower systemic exposures and reduce effectiveness of such medications

Watch the administration video for step-by-step instructions on how to properly administer RYSTIGGO

*RYSTIGGO is intended for subcutaneous administration using an infusion pump at a constant flow rate of up to 20 mL/hr.¹

Reference:

  1. RYSTIGGO [Prescribing Information]. Smyrna, GA: UCB, Inc.

UP NEXT

START PATIENTS with RYSTIGGO